How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,932 results for

Follicle Stimulating Hormone

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

221. Immunogenicity of Repeated Follicle Stimulating Hormone (FSH) Stimulation Cycles

Immunogenicity of Repeated Follicle Stimulating Hormone (FSH) Stimulation Cycles Immunogenicity of Repeated Follicle Stimulating Hormone (FSH) Stimulation Cycles - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Immunogenicity of Repeated Follicle Stimulating Hormone (FSH) Stimulation Cycles The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01785095 Recruitment Status : Completed First Posted : February 7, 2013 Results First Posted : March 27, 2015 Last Update Posted : February 9, 2017 Sponsor: IBSA

2013 Clinical Trials

222. Advantages of recombinant follicle-stimulating hormone over human menopausal gonadotropin for ovarian stimulation in intrauterine insemination: a randomized clinical trial in unexplained infertility. (Abstract)

Advantages of recombinant follicle-stimulating hormone over human menopausal gonadotropin for ovarian stimulation in intrauterine insemination: a randomized clinical trial in unexplained infertility. To compare two different gonadotropin preparations, human menopausal gonadotropin (hMG) and recombinant follicle-stimulating hormone (rFSH), combined with clomiphene citrate (CC) in women with unexplained infertility undergoing intrauterine insemination (IUI).In this prospective clinical trial (...) , couples prepared for IUI cycles were randomly allocated to two groups either to receive CC and hMG (group A, n=127) or CC and rFSH (group B, n=132) for ovarian stimulation. Outcomes including rates of clinical pregnancy, miscarriage, OHSS, multiple pregnancy, cancellation, and live birth were compared between groups.Duration of gonadotropin therapy was significantly shorter in group B (5.1±0.84 vs. 4.7±0.8 days, CI=95%, P<0.001). The total dose of administered gonadotropin was also significantly lower

2013 European journal of obstetrics, gynecology, and reproductive biology Controlled trial quality: uncertain

223. Simultaneous administration of human acidic and recombinant less acidic follicle-stimulating hormone for ovarian stimulation improves oocyte and embryo quality, and clinical outcome in patients with repeated IVF failures. (Abstract)

Simultaneous administration of human acidic and recombinant less acidic follicle-stimulating hormone for ovarian stimulation improves oocyte and embryo quality, and clinical outcome in patients with repeated IVF failures. Ovarian stimulation is an integral procedure in assisted reproduction treatment. It is achieved by the administration of exogenous gonadotropins to increase follicular recruitment and oocyte yield. Optimization of ovarian stimulation is an essential prerequisite (...) for the success of IVF treatment.This study aimed to evaluate the effect of a combined stimulation protocol of human FSH and recombinant FSH, simultaneously administered, on oocyte and embryo quality and clinical outcome.In a prospective randomized study 197 infertile patients with a history of previous IVF failures for at least 3-5 attempts, were enrolled for an in vitro fertilization treatment. All patients had a standard down-regulation with GnRH analog and were then stimulated with FSH. The patients were

2013 European review for medical and pharmacological sciences

224. Why we may abandon basal follicle-stimulating hormone testing: a sea change in determining ovarian reserve using antimüllerian hormone. (Abstract)

Why we may abandon basal follicle-stimulating hormone testing: a sea change in determining ovarian reserve using antimüllerian hormone. Antimüllerian hormone is the most informative serum marker of ovarian reserve currently available and should be considered an important part of any contemporary reproductive medicine practice. It is both more convenient and informative than basal FSH and can be assessed at any point in the cycle. It is the most useful serum method of determining ovarian reserve

2013 Fertility and Sterility

225. Antimüllerian hormone inhibits follicle-stimulating hormone-induced adenylyl cyclase activation, aromatase expression, and estradiol production in human granulosa-lutein cells. (Abstract)

Antimüllerian hormone inhibits follicle-stimulating hormone-induced adenylyl cyclase activation, aromatase expression, and estradiol production in human granulosa-lutein cells. To investigate the effects of antimüllerian hormone (AMH) on basal and FSH-induced cytochrome P450 aromatase (aromatase) expression and E2 production in human granulosa-lutein (hGL) cells, and to elucidate the mechanism by which AMH exerts its effects.Experimental study.Academic medical center for reproductive (...) science.The hGL cells were obtained from consenting patients undergoing IVF treatment.None.Primary cultures of hGL cells were used to examine the effects of AMH (10 ng/mL) on basal and FSH (0.2 IU/mL)-stimulated E2 and intracellular cyclic adenosine 3':5' monophosphate (cAMP) accumulation, as well as aromatase and FSH receptor expression. Small interfering RNA targeting type II AMH receptor (AMHR2) was used to verify the specificity of the effects.Treatment with AMH significantly reduced FSH-stimulated

2013 Fertility and Sterility

226. FSHB-211 and FSHR 2039 are associated with serum levels of follicle-stimulating hormone and antimüllerian hormone in healthy girls: a longitudinal cohort study. (Abstract)

FSHB-211 and FSHR 2039 are associated with serum levels of follicle-stimulating hormone and antimüllerian hormone in healthy girls: a longitudinal cohort study. To investigate whether genetic polymorphisms in the FSH pathway (FSHB-211 G→T and FSHR 2039 A→G) affect serum levels of FSH, antimüllerian hormone (AMH), and age at pubertal onset. FSH secretion and FSH signal transduction are enhanced in carriers of FSHB GG and FSHR AA, respectively. Furthermore, the combined genotype FSHB GG+FSHR AA (...) +FSHR AA may potentiate the FSH pathway, which increases serum levels of FSH and reduces AMH. Common variations in genes regulating follicle growth may affect AMH levels independently of the number of resting primordial follicles.Copyright © 2013 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

2013 Fertility and Sterility

227. Progesterone elevation does not compromise pregnancy rates in high responders: a pooled analysis of in vitro fertilization patients treated with recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in six trials. (Abstract)

Progesterone elevation does not compromise pregnancy rates in high responders: a pooled analysis of in vitro fertilization patients treated with recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in six trials. To compare the impact of elevated P during the late follicular phase on the chance of pregnancy in low, normal, and high responders.Retrospective combined analysis from six clinical trials.IVF centers.Women up to 39 years of age with a regular menstrual (...) cycle and an indication for ovarian stimulation before IVF/intracytoplasmic sperm injection.Ovarian stimulation with recombinant (r) FSH in a GnRH antagonist protocol.Ongoing pregnancy rates (OPRs) assessed with the use of univariate and multivariate analyses according to serum P levels ≤ 1.5 ng/mL versus >1.5 ng/mL on the day of hCG administration and compared among low (1-5 oocytes), normal (6-18 oocytes), and high (>18 oocytes) responders.A total of 157/1,866 women (8.4%; 95% confidence interval

2013 Fertility and sterility

228. Successful Pregnancies After Adequate Hormonal Replacement in Patients With Combined Pituitary Hormone Deficiencies (Full text)

of hormone replacement was determined. Patients were subjected to controlled ovarian stimulation (COS) for timed intercourse, intrauterine insemination, or in vitro fertilization, according to the presence or absence of other infertility factors (male or tubal).All women became pregnant. The number of COS attempts until pregnancy was achieved varied between 1 and 5. The duration of COS resulting in at least one dominant follicle varied between 9 and 28 days, and total gonadotropin consumed varied between (...) 1200 and 3450 IU. Two patients with severely suppressed basal gonadotropin levels since an early age had a cancelled COS cycle. All pregnancies were singleton except one (monochorionic twin gestation). The gestational ages at birth ranged from 35 weeks to 39 weeks and 4 days; three patients underwent cesarean section, and two had vaginal deliveries. Only one newborn was small for gestational age (delivered at 35 weeks).Adequate hormonal replacement prior to ovarian stimulation resulted

2017 Journal of the Endocrine Society PubMed abstract

229. Hormone Therapy in Primary Ovarian Insufficiency

younger than 40 years who have elevated follicle-stimulating hormone levels in the menopausal range (at least 30–40 mIU/mL) and amenorrhea (1, 3, ). This clinical state, traditionally referred to as “premature menopause” or “premature ovarian failure,” affects 1% of women. The term “primary ovarian insufficiency” more accurately captures the nature of ovarian dysfunction displayed in affected women, 50% of whom experience infrequent ovulation and menstrual cycles after diagnosis and 5–10% of whom may (...) as of the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Hormone Therapy in Primary Ovarian Insufficiency ABSTRACT: Primary ovarian insufficiency describes a spectrum of declining ovarian function and reduced fecundity due to a premature decrease in initial follicle number, an increase in follicle destruction, or poor follicular response to gonadotropins. The sequelae of primary ovarian insufficiency

2017 American College of Obstetricians and Gynecologists

230. Degarelix for treating advanced hormone-dependent prostate cancer

the risk of cardiovascular events in people with pre-existing cardiovascular disease, including suppression of both luteinising hormone and follicle-stimulating hormone and degarelix's potential effect of reducing inflammation linked with atherosclerosis. The committee noted comments received during consultation outlining the potential benefits of degarelix compared with LHRH agonists in people with pre-existing cardiovascular disease, and discussed in detail the clinical evidence presented (...) hormone antagonist that reduces the release of gonadotrophins by the pituitary, which in turn reduces the secretion of testosterone by the testes. Gonadotrophin-releasing hormone is also known as luteinising hormone- releasing hormone. Because gonadotrophin-releasing hormone antagonists do not produce a rise in hormone levels at the start of treatment, there is no initial testosterone surge or tumour stimulation, and therefore no potential for symptomatic flares. Degarelix has a marketing

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

231. Specific Protein Kinase C Isoforms α And βI Are Involved in Follicle-Stimulating Hormone-Induced Mouse Follicle-Enclosed Oocytes Meiotic Resumption (Full text)

Specific Protein Kinase C Isoforms α And βI Are Involved in Follicle-Stimulating Hormone-Induced Mouse Follicle-Enclosed Oocytes Meiotic Resumption Protein kinase C (PKC) is involved in gonadotrophin-induced oocyte maturation. In the present study, we investigated the role of specific PKC isoforms in the process of follicle-stimulating hormone (FSH)-induced oocyte meiotic resumption. Small antral follicles (200-300 µm in diameter) were isolated from immature mice and cultured in vitro. FSH (...) significantly induced follicle-enclosed oocytes (FEOs) meiotic resumption after 8 hr culture. However, the induced effect of FSH was dose-dependently inhibited by the specific PKC α and βI inhibitor Gö6976, and 100 nM Gö6976 completely blocked FSH function in oocyte meiotic resumption. Furthermore, FSH dramatically induced the expression of transcripts encoding epidermal growth factor (EGF)-like growth factors Areg, Btc, and Ereg mRNA levels, and up-regulated tyrosine phosphorylation level of EGF receptor

2012 PloS one PubMed abstract

232. Follicle-Stimulating Hormone Abnormalities (Treatment)

Follicle-Stimulating Hormone Abnormalities (Treatment) Follicle-Stimulating Hormone Abnormalities Treatment & Management: Medical Care, Surgical Care, Consultations Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTE4ODEwLXRyZWF0bWVudA== processing > Follicle-Stimulating Hormone Abnormalities Treatment & Management Updated: Mar 12, 2018 Author: Serge A Jabbour, MD, FACP, FACE; Chief Editor: George T Griffing, MD Share Email Print Feedback Close Sections Sections Follicle-Stimulating Hormone Abnormalities Treatment Medical Care Medical treatment in patients with abnormal levels of follicle-stimulating hormone (FSH) depends on the underlying etiology. Appropriate articles are available that contain detailed discussions

2014 eMedicine.com

233. Follicle-Stimulating Hormone Abnormalities (Overview)

Follicle-Stimulating Hormone Abnormalities (Overview) Follicle-Stimulating Hormone Abnormalities: Practice Essentials, Pathophysiology, Epidemiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTE4ODEwLW92ZXJ2aWV3 processing > Follicle-Stimulating Hormone Abnormalities Updated: Mar 12, 2018 Author: Serge A Jabbour, MD, FACP, FACE; Chief Editor: George T Griffing, MD Share Email Print Feedback Close Sections Sections Follicle-Stimulating Hormone Abnormalities Overview Practice Essentials Follicle-stimulating hormone (FSH) is a glycoprotein gonadotropin secreted by the anterior pituitary in response to gonadotropin-releasing hormone (GnRH) released by the hypothalamus. The pituitary gland also secretes

2014 eMedicine.com

234. Follicle-Stimulating Hormone Abnormalities (Follow-up)

Follicle-Stimulating Hormone Abnormalities (Follow-up) Follicle-Stimulating Hormone Abnormalities Treatment & Management: Medical Care, Surgical Care, Consultations Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTE4ODEwLXRyZWF0bWVudA== processing > Follicle-Stimulating Hormone Abnormalities Treatment & Management Updated: Mar 12, 2018 Author: Serge A Jabbour, MD, FACP, FACE; Chief Editor: George T Griffing, MD Share Email Print Feedback Close Sections Sections Follicle-Stimulating Hormone Abnormalities Treatment Medical Care Medical treatment in patients with abnormal levels of follicle-stimulating hormone (FSH) depends on the underlying etiology. Appropriate articles are available that contain detailed discussions

2014 eMedicine.com

235. Follicle-Stimulating Hormone Abnormalities (Diagnosis)

Follicle-Stimulating Hormone Abnormalities (Diagnosis) Follicle-Stimulating Hormone Abnormalities: Practice Essentials, Pathophysiology, Epidemiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTE4ODEwLW92ZXJ2aWV3 processing > Follicle-Stimulating Hormone Abnormalities Updated: Mar 12, 2018 Author: Serge A Jabbour, MD, FACP, FACE; Chief Editor: George T Griffing, MD Share Email Print Feedback Close Sections Sections Follicle-Stimulating Hormone Abnormalities Overview Practice Essentials Follicle-stimulating hormone (FSH) is a glycoprotein gonadotropin secreted by the anterior pituitary in response to gonadotropin-releasing hormone (GnRH) released by the hypothalamus. The pituitary gland also secretes

2014 eMedicine.com

236. Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF (Full text)

(number and quality of oocytes) in women aged 20 to 40 years, who were undergoing stimulation before in vitro fertilisation (IVF). Interventions The AMH-guided controlled ovarian hyperstimulation was compared against the conventional hyperstimulation, which was guided by chronological age and follicle stimulating hormone (FSH) level. In the AMH strategy, women with acceptable AMH levels were grouped into three categories (optimal, satisfactory, or low fertility), which determined their stimulation (...) Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF Yates AP, Rustamov O, Roberts SA, Lim HY, Pemberton PW, Smith A, Nardo LG Record Status This is a critical abstract of an economic

2011 NHS Economic Evaluation Database. PubMed abstract

237. Genetic variations altering FSH action affect circulating hormone levels as well as follicle growth in healthy peripubertal girls. (Full text)

Genetic variations altering FSH action affect circulating hormone levels as well as follicle growth in healthy peripubertal girls. Do variants of the genes encoding follicle stimulating hormone (FSH) beta subunit (B) and FSH receptor (R) impact circulating reproductive hormone levels and ovarian follicle maturation in healthy peripubertal girls?FSHB and FSHR genetic variants exert, alone or their combination, distinct effects on reproductive hormone levels as well as ovarian follicle maturation (...) ) and the Copenhagen Mother-Child Cohort (1997-2002, including transabdominal ultrasound (TAUS) of the ovaries in a subset of 91 peripubertal girls).Clinical examinations, including pubertal breast stage (Tanner's classification B1-B5) were performed. Circulating levels of FSH, luteinizing hormone (LH), estradiol, anti-Mullerian hormone (AMH) and inhibin-B were assessed by immunoassays. In a subset of the girls (n = 91), ovarian volume and the number/size of antral follicles were assessed by TAUS. Genotypes were

2016 Human Reproduction PubMed abstract

238. Interrelationships among reproductive hormones and antral follicle count in human menstrual cycles (Full text)

, progesterone, inhibin A, inhibin B and anti-mullerian hormone (AMH) were measured in serum collected every 1-3 days across one interovulatory interval (IOI) from 26 healthy women aged 18-50 years. The antral follicle count (AFC) for follicles 2-5 mm, >6 mm and 2-10 mm were tabulated across the IOI. Independent associations between ovarian hormones/AFC vs pituitary follicle-stimulating hormone (FSH) and luteinising hormone (LH) were investigated using multivariate regression analysis. The data were sub (...) Interrelationships among reproductive hormones and antral follicle count in human menstrual cycles It is recognised that ovarian factors, including steroid and protein hormones, are critical in the feedback regulation of pituitary gonadotropins; however, their individual contributions are less defined. The aim of this study was to explore the reciprocal relationships between ovarian and pituitary hormones across the normal ovulatory menstrual cycle as women age. FSH, LH, oestradiol

2016 Endocrine connections PubMed abstract

239. Luteinizing Hormone Causes Phosphorylation and Activation of the cGMP Phosphodiesterase PDE5 in Rat Ovarian Follicles, Contributing, Together with PDE1 Activity, to the Resumption of Meiosis (Full text)

Luteinizing Hormone Causes Phosphorylation and Activation of the cGMP Phosphodiesterase PDE5 in Rat Ovarian Follicles, Contributing, Together with PDE1 Activity, to the Resumption of Meiosis The meiotic cell cycle of mammalian oocytes in preovulatory follicles is held in prophase arrest by diffusion of cGMP from the surrounding granulosa cells into the oocyte. Luteinizing hormone (LH) then releases meiotic arrest by lowering cGMP in the granulosa cells. The LH-induced reduction of cGMP (...) is caused in part by a decrease in guanylyl cyclase activity, but the observation that the cGMP phosphodiesterase PDE5 is phosphorylated during LH signaling suggests that an increase in PDE5 activity could also contribute. To investigate this idea, we measured cGMP-hydrolytic activity in rat ovarian follicles. Basal activity was due primarily to PDE1A and PDE5, and LH increased PDE5 activity. The increase in PDE5 activity was accompanied by phosphorylation of PDE5 at serine 92, a protein kinase A/G

2016 Biology of reproduction PubMed abstract

240. Effects of aqueous extract from Asparagus officinalis L. roots on hypothalamic-pituitary-gonadal axis hormone levels and the number of ovarian follicles in adult rats (Full text)

microscope.Dose-dependent aqueous extract of asparagus roots significantly increased serum levels of GnRH, FSH, LH, estrogen, and progestin hormones compared to control and sham groups. Increase in number of ovarian follicles and corpus luteum in groups treated with asparagus root extract was also observed (p<0.05).Asparagus roots extract stimulates secretion of hypothalamic- pituitary- gonadal axis hormones. This also positively affects oogenesis in female rats. (...) Effects of aqueous extract from Asparagus officinalis L. roots on hypothalamic-pituitary-gonadal axis hormone levels and the number of ovarian follicles in adult rats Asparagus is a plant with high nutritional, pharmaceutical, and industrial values.The present study aimed to evaluate the effect of aqueous extract of asparagus roots on the hypothalamic-pituitary-gonadal axis hormones and oogenesis in female rats.In this experimental study, 40 adult female Wistar rats were divided into five

2016 International Journal of Reproductive Biomedicine PubMed abstract

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>